CN1264547C - 一种治疗冠心病心绞痛的中药制剂及其制备方法 - Google Patents
一种治疗冠心病心绞痛的中药制剂及其制备方法 Download PDFInfo
- Publication number
- CN1264547C CN1264547C CN 200410024546 CN200410024546A CN1264547C CN 1264547 C CN1264547 C CN 1264547C CN 200410024546 CN200410024546 CN 200410024546 CN 200410024546 A CN200410024546 A CN 200410024546A CN 1264547 C CN1264547 C CN 1264547C
- Authority
- CN
- China
- Prior art keywords
- preparation
- radix
- present
- chinese medicine
- angina pectoris
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 22
- 208000029078 coronary artery disease Diseases 0.000 title abstract description 10
- 239000007788 liquid Substances 0.000 claims abstract description 23
- 241000222336 Ganoderma Species 0.000 claims abstract description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 8
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 235000008434 ginseng Nutrition 0.000 claims abstract description 8
- 239000006188 syrup Substances 0.000 claims abstract description 8
- 235000020357 syrup Nutrition 0.000 claims abstract description 8
- 239000006187 pill Substances 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 239000000843 powder Substances 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241000208340 Araliaceae Species 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 239000006196 drop Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims 2
- 238000002481 ethanol extraction Methods 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 7
- 230000002936 tranquilizing effect Effects 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 3
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000208688 Eucommia Species 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 244000126002 Ziziphus vulgaris Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000012907 honey Nutrition 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 238000000605 extraction Methods 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 9
- 239000000284 extract Substances 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 210000003127 knee Anatomy 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 206010013954 Dysphoria Diseases 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 208000009205 Tinnitus Diseases 0.000 description 4
- -1 antiseptic Polymers 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 206010029410 night sweats Diseases 0.000 description 4
- 230000036565 night sweats Effects 0.000 description 4
- 238000004064 recycling Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 231100000886 tinnitus Toxicity 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 206010040007 Sense of oppression Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
例数 | 显效 | 有效 | 无效 | 加重 | 总有效率 | |
治疗组 | 150 | 60(40.00%) | 84(56.00%) | 6(4.00%) | 0 | 96.00% |
例数 | 心绞痛起效时间(天) | 心绞痛消失时间(天) | |
治疗组 | 150 | 9.14±3.68 | 19.93±4.54 |
显效例% | 有效例% | 无效例% | 加重例% | 总有效率 | |
治疗组 | 33(22.00%) | 45(30.00%) | 72(48.00%) | 0 | 52.00% |
例 | 临床控制 | 显效 | 有效 | 无效 | 总有效率% | 控显率% | |||||
n | % | n | % | n | % | n | % | ||||
冶疗组 | 150 | 24 | 16.00% | 51 | 34.00% | 69 | 46.00% | 6 | 4.00% | 96.00% | 50.00% |
证候 | 治疗组(n=50) | ||
治疗前(n) | 治疗后(n) | 消失率(%) | |
心胸隐痛胸闷气短心悸盗汗心烦不寐腰膝酸软耳鸣头晕舌红或有紫斑脉细数 | 15015014111790936372126123 | 61874563245537275260 | 59.3342.0068.0946.1573.3340.8641.2762.558.7351.22 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410024546 CN1264547C (zh) | 2004-08-11 | 2004-08-11 | 一种治疗冠心病心绞痛的中药制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410024546 CN1264547C (zh) | 2004-08-11 | 2004-08-11 | 一种治疗冠心病心绞痛的中药制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1626195A CN1626195A (zh) | 2005-06-15 |
CN1264547C true CN1264547C (zh) | 2006-07-19 |
Family
ID=34763365
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410024546 Active CN1264547C (zh) | 2004-08-11 | 2004-08-11 | 一种治疗冠心病心绞痛的中药制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1264547C (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101843758B (zh) * | 2009-12-09 | 2011-12-21 | 北京绿源求证科技发展有限责任公司 | 一种治疗冠心病的中药 |
CN105267690A (zh) * | 2015-03-17 | 2016-01-27 | 孔冬梅 | 一种治疗心绞痛的中药 |
CN106361889B (zh) * | 2016-08-31 | 2019-10-22 | 单晓春 | 养心调肾颗粒及其制备方法和应用 |
CN107714849A (zh) * | 2017-11-16 | 2018-02-23 | 广西博白县华春福家庭农场 | 一种治疗心肌缺血的中药组合物及其制备方法 |
-
2004
- 2004-08-11 CN CN 200410024546 patent/CN1264547C/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN1626195A (zh) | 2005-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101711848B (zh) | 一种辅助治疗肿瘤的中药组合物 | |
CN1302796C (zh) | 治疗妇女亚健康疲劳综合症的中药制剂及其制备方法 | |
CN101856405B (zh) | 一种治疗2型糖尿病的药物组合物及其制备方法 | |
CN1264547C (zh) | 一种治疗冠心病心绞痛的中药制剂及其制备方法 | |
CN101564464B (zh) | 一种调节肿瘤患者机体免疫力的中药药物 | |
CN103055019A (zh) | 治疗脑血栓的冻干鲜地黄 | |
CN104225425A (zh) | 一种提高免疫力、改善睡眠、预防心脑血管疾病的中药制剂及其制备方法 | |
CN101249158B (zh) | 一种用于预防和治疗心脑血管疾病的中药制剂及制备方法 | |
CN103272176A (zh) | 一种治疗心血管疾病的中药组合物及其制备方法 | |
CN102552520A (zh) | 一种治疗胸痹心痛的活血止痛药物及制备工艺和应用 | |
CN100540025C (zh) | 治疗帕金森病的中药制剂及其制备方法 | |
CN1182862C (zh) | 一种治疗冠心病心绞痛的中药制剂及其制备方法 | |
CN105561184A (zh) | 一种用于活血化瘀温经通络的药物组合物及其制备方法 | |
CN104825817A (zh) | 一种具有抗肿瘤作用的中药制剂 | |
CN101455813A (zh) | 一种改善记忆、治疗健忘的中药制剂及其制备方法 | |
CN104825784B (zh) | 一种具有抗胃癌活性的中药组合物及其制备方法和应用 | |
CN101637533B (zh) | 一种中药组合物在制备治疗病毒性心肌炎药物中的应用 | |
CN103479868B (zh) | 一种治疗心虚胆怯型心律失常的中药及制备方法 | |
CN108295040A (zh) | 愈心痛胶囊制备方法 | |
CN100339093C (zh) | 一种治疗冠心病、心绞痛的复方药物及其制备方法 | |
CN1127968C (zh) | 一种治疗白癜风病口服药物及其制造方法 | |
CN1927366A (zh) | 一种用于慢性肠胃炎的中药组合物 | |
CN1634541A (zh) | 治疗疲劳综合症、防止早衰的药物及其制备方法 | |
CN100335111C (zh) | 一种治疗风湿病的药物及其制备方法 | |
CN101601789B (zh) | 一种治疗脂质沉积性肌病的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANDONG C.P. FREDA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LING PEIXUE Effective date: 20091225 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20091225 Address after: Lunan Road, hi tech Zone, Shandong, Ji'nan Patentee after: Shandong Mingren Furuida Pharmaceutical Co.,Ltd Address before: No. 264 mountain road, Lixia District, Shandong, Ji'nan Patentee before: Ling Peixue |
|
C53 | Correction of patent for invention or patent application | ||
C56 | Change in the name or address of the patentee | ||
CB03 | Change of inventor or designer information |
Inventor after: Ling Peixue Inventor after: Zhang Ling Inventor after: Pang Xiaoyang Inventor after: Cui Yan Inventor before: Ling Peixue Inventor before: Zhang Ling Inventor before: Jing Rui Inventor before: Wang Huan Inventor before: Qu Yanwei Inventor before: Pang Xiaoyang Inventor before: Cui Yan |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LING PEIXUE ZHANG LING JING RUI WANG HUAN QU YANWEI PANG XIAOYANG CUI YAN TO: LING PEIXUE ZHANG LING PANG XIAOYANG CUI YAN |
|
CP03 | Change of name, title or address |
Address after: Hi tech District Ji'nan city Shandong province 250104 Road No. 3333 Patentee after: Shandong Mingren Furuida Pharmaceutical Co., Ltd. Address before: 250104 Lunan Road, Ji'nan hi tech Zone, Shandong Patentee before: Shandong Mingren Furuida Pharmaceutical Co.,Ltd |